Journal
BRITISH JOURNAL OF PSYCHIATRY
Volume 195, Issue -, Pages S29-S36Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjp.195.52.s29
Keywords
-
Categories
Funding
- Janssen-Cilag
- Servier
- Eli Lilly
- BMS/Otsuka
Ask authors/readers for more resources
Background Second-generation antipsychotics (SGAs) represent an advance in the long-term management of schizophrenia. Aims To review the available evidence concerning SGA long-acting injections (LAIs). Method A systematic review of the literature was conducted using PubMed. Results Risperidone long-acting injection was the first licensed SGA-LAI compound and is effective in the long-term management of schizophrenia, with a safety profile similar to that of oral risperidone. Olanzapine pamoate has recently been approved in Europe. In terms of efficacy, at injection intervals of up to 4 weeks it appears comparable to oral olanzapine, although the potential for 'post-injection syndrome' (delirium) calls for additional safety considerations. Paliperidone palmitate is currently under review with the licensing authorities. it also affords the potential advantage of monthly dosing. Conclusions More long-term comparisons of SGA-LAIs with oral SGAs as well as with first-generation antipsychotic LAIs are needed. These studies should include cost-effectiveness data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available